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ABSTRACT

Received:

The well-defined and characterized 3D crystal structure of a protein is important
to explore the topological and physiological features of the protein. The distinguished
topography of a protein helps medical chemists design drugs on the basis of the pharmacophoric features of the protein. Structure-based drug discovery, specifically for pathological proteins that cause a higher risk of disease, takes advantage of this fact. Current
tools for studying drug-protein interactions include physical, chromatographic, and electrophoretic methods. These techniques can be separated into either non-spectroscopic
(equilibrium dialysis, ultrafiltration, ultracentrifugation, etc.) or spectroscopic (Fluorescence spectroscopy, NMR, X-ray diffraction, etc.) methods. These methods, however,
can be time-consuming and expensive. On the other hand, in silico methods of analyzing
protein-drug interactions, such as docking, molecular simulations, and High-Throughput
Virtual Screenings (HTVS), are heavily underutilized by core drug discovery laboratories. These kinds of approaches have a great potential for the mass screening of potential
small drugs molecules. Studying protein-drug interactions is of particular importance
for understanding how the structural conformation of protein elements affect overall
ligand binding affinity. By taking a bioinformatics approach to analyzing drug-protein
interactions, the speed with which we identify potential drugs for genetic targets can be
greatly increased.
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Introduction
Cancer is the second leading cause of death in the United States
and serves as a great barrier to increasing life expectancy in many
countries around the world [1]. In fact, below the age of 70, cancer
is the first or second leading cause of death in 112 of 183 countries

and is the third or fourth cause of death in another 23 countries [2].
Although the overall incidence and cancer mortality rate has been
greatly reduced over the past couple of years due to advancements
in early detection screenings and treatment options, cancer
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remains prevalent [3]. Factors that increase risk of cancer, like
obesity, diabetes, and aging, are on the rise, and as a result, people
are at a higher risk of getting cancer, especially in the United States
[4]. Furthermore, treatment options are becoming more limited
due to the robust characteristics of aggressive cancer types that
allows them to obtain drug resistance. This is especially true for
the adolescence and young adult (AYA) population, as from 20062017, an increase in overall cancer incidence was seen, which is bad
because treating younger cancer patients means that the cancer
has more time to build up a resistance to the anticancer drug being
used. Because of this, research into the development of new drugs
for cancer treatment has been an ongoing effort.

Drug resistance for typical chemotherapeutic treatments is one
of the main reasons these kinds of cancer therapies result in failure
[5]. Despite the considerable progress being made in targeted
cancer therapies, there is no treatment that is 100% effective in
eliminating cancers, because of their innate resistance (to a broad
range of anticancer drugs) or their acquired resistance (as existing
therapies become more effective against them) [6]. One reason for
this resistance may be due to cancer cell plasticity, which allows for
cancer cells to switch between differentiated (limited tumorigenic
potential) and undifferentiated (cancer stem cells) states [7].
Plasticity greatly contributes
to tumor heterogeneity,
which describes the differences between subpopulations of
the same tumor type in different patients and is the reason why
differential responses to therapies occur [8]. Furthermore, cancers
are extremely complex, and their robustness [9,10] allows them
to survive, adapt, and maintain their proliferative potential and
functionality in the face of any internal or external perturbations
(such as against a wide variety of anticancer therapies) [11]. One
major solution to this is to develop novel drugs that are either better
than their predecessors or that can result in deeper responses from
being used sequentially or in combination with existing drugs [12].

Proteins as Therapeutic Targets

The diagnostic detection and measurement of cancer progression is essential for effective disease management, especially since
the early stages of cancer have the highest therapeutic potential
[13]. These early stages, however, are typically asymptomatic, and
as a result, identifying novel biomarkers of various cancers is essential for early detection [14]. Cancer biomarkers can be any sort of
tumor characteristic (like tumor tissue) or bodily response to cancer (like bodily fluids), that help indicate current or future cancer
behavior, such as cancer risk, cancer type, and drug or treatment efficacy [15]. Not only can these biomarkers be used in diagnosis and
early malignancy detection, but they may also be used as specific
drug targets when designing novel anticancer drugs.

A prominent example of cancer biomarkers include the
estrogen receptor (ER), the progesterone receptor (PR), and the
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human epidermal growth factor receptor (HER2), all of which are
essential for the standard care of newly diagnosed, recurring, and
malignant breast cancer patients [16]. Targeted HER2 drugs, such
as Tratsuzumab, a humanized monoclonal antibody against HER2,
have been developed and shown to increase time to progression
and survival in both early stage and metastatic breast cancers [17].
As cancers continue to develop drug resistance, it becomes more
critical to identify new biomarkers and develop more efficient drugs
to help combat disease progression [18]. Current tools for doing
this are time-consuming and inefficient, but the latest structural
modeling tools can make this process easier and faster and can even
take advantage of existing drug databases to potentially repurpose
known drugs.

Methods for Drug Identification

The cancer proteome and metabolome (the entire set of
proteins or small molecule metabolites, respectively, that are
produced by a cancer), can contain important information relating
to the discovery of novel biomarkers. Various methods such as
electrophoresis, mass-spectroscopy techniques, and protein
microarrays can be used to discover novel biomarkers. Additionally,
many target-specific immunoassays and immunosensor techniques,
including electrochemical, mass-sensitive, and optical have been
used for tumor-related biomarker detection [19]. Traditional
chemotherapies directly target the DNA of cells, but this can damage
healthy cells, so modern approaches to anticancer drugs focus on
molecular targeted therapy (i.e. monoclonal antibodies and small
molecule inhibitors) to reverse abnormalities in the expression of
kinases, tubulin proteins, extracellular matrix components, vascular
targets, cancer stem cell pathways, or the tumor microenvironment
(like acidity) as possible drug targets so that cancer cells can be
selectively killed with a decreased toxicity towards normal cells
[20].

Physical methods for studying drug-protein binding have
been traditionally divided into either non-spectroscopic (like
calorimetry, dialysis, filtration, electrophoresis and centrifugation)
or spectroscopic (like UV and visible light absorption, NMR, X-rays,
and fluorescence) [21]. These, however, have been replaced with
more advanced and efficient methods such as a variety of massspectroscopy (MS) techniques including a direct approach, a
structural approach, an enzymatic approach, an affinity-based
approach, and a global proteomics approach [22]. These various
MS approach make it possible to characterize drug target
structures, screen large numbers of potential drug candidates (in
metabolism and in pharmacokinetic studies), detect drug-target
complexes, examine how protein structure is affected by the drug,
and monitor the enzymatic activity of the target protein in relation
to the drug [23]. Despite these major improvements in analyzing
protein-drug interactions, these methods remain complex, time-
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consuming, and costly [24]. As a result, more convenient tools, such
as computational methods and structural modeling, should be used
for estimating protein-drug binding affinities instead.

Structural Modeling and Drug Bank

The RCSB protein data bank (PDB) is an open access resource
in biology and medicine for finding three-dimensional structural
data on large biological molecules such as proteins and can be used
to find the PDB ID for the crystal structure of a protein of interest
(Ex: HER2) [25]. All 3D structures found on this resource are
experimentally verified by either X-ray crystallography or nuclear
magnetic resonance (NMR) and give an accurate depiction of the
structure of the protein and/or its binding domain. This makes
it perfectly valid for in silico use and for extrapolating that data
towards in vitro and in vivo studies. Furthermore, a comprehensive
list of potential inhibitors, agonists, and antagonists can be
obtained from a variety of existing sources. For example, the
Natural Product Activity & Species Source Database (NPASS) can
be used to find potential nutraceuticals that are effective against
the protein of interest or use that data to develop a novel drug that
is analogous in structure [26]. Alternatively, the DrugBank library,
a comprehensive open access database containing information on
drugs, drug properties, and drug targets, may be used to screen
approved and experimental drugs to find effective inhibitors of the
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protein of interest [27].

This can all be accomplished in a matter of days or weeks by
performing a multi-layered High-Throughput Virtual Screening
(HTVS) with the BIOVIA Discovery Studio Client 2020 software. In
a multi-layered HTVS, several screening layers are performed in
succession to identify the best molecule that will bind to the protein
of interest [28]. This process takes place in three stages, each of which
sequentially narrows down the list of potential inhibitors. First, a
preliminary rigid docking analysis, using the DS LibDock extension,
takes place by comparing the binding energies of the protein’s
crystalline structure to each ligand from the identified drug library
in a rigid conformation to determine which ligands best fit at the
binding site. Then, a flexible docking analysis, using the CDOCKER
extension, takes place by mimicking the flexible nature of the
binding site domain in nature and produces docked conformations
with extreme precision. The number of potential drugs is then
finalized after an Absorption, Distribution, Metabolism, Excretion,
and Toxicity (ADMET) analysis is performed to determine the exact
pharmacokinetic properties of the protein-drug interactions that
were identified. Typically, after completion, anywhere from 10-20
drugs are identified and can then undergo further testing via in
vitro and in vivo analyses to confirm their potential for inhibition.
Figure 1 summarizes the steps in identification of drugs through
structural modeling.

Figure 1: Steps in identification of drugs through structural modeling. RCSB PDB is analyzed for the specific protein ID. The 3D
structure of the protein of interest, which is verified by X Ray crystallography or NMR, is used for further analysis. Identified
binding domains are screened on different drug bank libraries on the basis of different parameters (n= is the depiction for the
total target number).
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Conclusion
Using these underutilized in silico tools will save a lot of time and
money when considering the alternatives that are much more labor
and resource intensive. For example, High-Throughput Screenings
(HTS) are similar to HTVS except they are performed physically
under wet-lab conditions. HTS is a drug discovery process that
is popular amongst many pharmaceutical companies and takes
advantage of robotics to autonomously screen a library of drugs
and test their biological functions for pharmacological profiling
[29]. The problem is that the equipment required (robots) and
the bioactive drug screening libraries can cost tens of thousands
of dollars, require technical training to use precisely, and can take
months to finish a large screening analysis. Furthermore, from the
ADMET analysis, HTVS can analyze pharmacokinetic parameters,
like toxicity, of the identified drugs and their potential impact on
certain tissues, like the liver, something which requires further
testing after completion of HTS.

On top of all that, once this process is completed, a new drug
is not discovered. Rather, these molecules are identified as “leads”
for furthering and optimizing the drug discovery process, which
takes too long to be feasible for immediate use. In fact, from lab
experimentation to clinical testing and drug approval, novel drug
development is a complex, time-consuming, and expensive process
that can cost a manufacturer million, sometimes even billions [30] of
dollars in resources and 12-15 years for completion [31]. By taking
advantage of the latest bioinformatics techniques, such as HTVS,
to analyze protein-drug interactions, small molecule inhibitors
for cancer protein targets can be found with ease by repurposing
existing drugs instead of waiting years for new drug approval.
The potential for repurposing existing drugs as antagonists for
novel cancer protein targets shows great promise and should be
a more frequently explored option by pharmaceutical companies
worldwide.
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